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1. Introduction  
Leprosy is a chronic infectious disease cause by the Mycobacterium leprae. The disease is 
found worldwide, especially, in countries situated in tropical and subtropical regions. 
According to the reports of the World Health Organization (WHO) the global registered 
prevalence of leprosy at the beginning of 2010 stood at 211,903 cases, whereas the number of 
new cases detected during 2009 was 244,796 (World Health Organization [WHO], 2010). 
Although there has been a declining trend in prevalence and detection of new cases, leprosy 
is still a public health problem in Brazil. In 2009, the prevalence rate of the disease was 1.99 
per 10,000 habitants and 37,610 new cases of leprosy were detected in the entire country 
(Brazilian Ministry of Health, 2011). On the other hand, the Human deficiency Virus (HIV) 
infection is one of the greatest health problems of the world due to its pandemic nature and 
high morbidity and mortality rates. In the absence of treatment, the Acquired 
immunodeficiency syndrome (AIDS) usually leads to premature death. The World Health 
Organization estimates that 33.3 million people were living with HIV in the end of 2009 
around the globe and 2.6 million people became HIV infected in 2009 (Joint United Nations 
Programme on HIV/AIDS [UNAIDS], 2010). In Brazil, the AIDS epidemic has been 
maintained stable in the last few years. In 2009, the incidence rate was 20.1 per 100,000 
habitants and 38,538 new cases of AIDS were registered in the country (Brazilian Ministry of 
Health, 2010). Although the prevalence rate of coinfected individuals has never been 
estimated neither in Brazil nor worldwide, leprosy and the HIV infection seem to overlap in 
a number of countries, mainly in Africa and Asia continents. 
As observed with others Mycobacterial infections, it has been speculated that HIV and 
Mycobacterium leprae coinfection could exacerbate the pathogenesis of leprosy lesions and/ 
or could lead to increased susceptibility of leprosy. However, up to date, HIV infection has 
not seemed to modify the epidemiology and the natural course of leprosy (Ustianowski et 
al., 2006). In contrast, initiation of anti-retroviral treatment has been reported to be 
associated with activation of sub-clinical M. leprae infection and exacerbation of existing 
leprosy lesions (Menezes et al., 2009).   
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It is well known that highly active anti-retroviral therapy (HAART) in HIV patients is 
associated with dramatic reduction of HIV viral load and subsequent increase in CD4 T 
lymphocytes and immune function. While the recovery of the immune system results in 
clinical benefits and decrease in the incidence of opportunistic diseases and death, a subset 
of patients experience clinical deterioration after HAART is initiated.  This phenomenon is 
termed immune reconstitution inflammatory syndrome (Muller et al., 2010). This entity 
describes a collection of different inflammatory disorders which is associated with 
paradoxical worsening of symptoms and signs related to sub-clinical or preexisting 
infectious as well as of non infectious processes following HAART introduction (Hirsch et 
al., 2004). IRIS seems to result from dysfunction of some aspects of the immune system that 
affect the restoration of pathogen specific immune response and/ or immune regulation 
(French, 2009). The immunopathology of IRIS is poorly understood but it seems to be highly 
determined by the provoking pathogen. In this way, inflammation in Mycobacterial 
infections is often associated with characteristics of a TH1 immune response (French et al., 
2009). The sudden clinical deterioration associated with IRIS can be at times fatal and needs 
prompt intervention (Murdoch et al., 2007). The incidence of IRIS is not well know but it has 
been described ranging from less than 10% to more than 50%(Muller et al., 2010). 
Some evidences suggest that antiretroviral therapy can accelerate the onset of leprosy 
symptoms. In a retrospective cohort study, Sarno et al has demonstrated that in those 
individuals who initiated HAART the length of time covered up to leprosy diagnosis was 
significantly shorter than in those not receiving HAART (p=0,01) (Sarno et al., 2008). In 
another study, in the Amazon region of Brazil, seven patients out of 25 presented leprosy as 
manifestation of IRIS (Talhari et al., 2010). One study, in French Guyana, has observed that 
the incidence of leprosy was higher in HIV patients receiving HAART for less than 3 months 
than in HIV untreated patients (13 against 0,7 per 1,000 person-year, p=0,02) (Couppié et al., 
2009). Another study, in India, has found a high incidence of leprosy of 5.22 per 1,000 
person-year in HIV patients on HAART (Vinay et al., 2009).  Several case reports of leprosy 
associated with IRIS have been published in the literature (Martiniuk et al., 2007; Chow et 
al., 2009), including one of histoid leprosy case (Bumb et al., 2010). 
Currently, it is widely accepted that the reconstitution of the immune function observed in 
HIV patients on HAART can trigger leprosy reaction. Leprosy reactions are immune-
inflammatory events that complicate the disease. The frequency of reaction has been 
reported to range from 2.6% to 20% of PB patients (Becx-Bleumink & Berhe, 1992) and from 
15% to 60% of MB cases (Bwire R & Kawuma HJ, 1994; Nery JAC et al., 1998). It is broadly 
accepted that reaction is the result of a shift in the patient´s level of inflammation and/or 
cell- mediated immunity which, in turn, leads to accelerated nerve damage and serious 
physical disabilities (Sarno et al., 2008). It is frequently observed during multidrug therapy 
(MDT), but it may be developed before or after leprosy treatment. These reactional states are 
classified as type 1 (Reversal Reaction) or Type 2 (Erithema Nodosum Lepromatosum) 
reaction depending on the clinical characteristics of the acute episode and its immune 
background. Strong evidences currently indicates that reversal reactions are the result of an 
enhancement of cellular immunity and delayed hypersensitivity to M. leprae antigens, but 
both the precipitating factors and the physiopathological mechanisms involved remain ill-
defined (Scollard et al., 2006). Reversal reaction is clinically characterized by the worsening 
of previous leprosy lesion or appearance of new infiltrated, erythematous plaques. It may be 
accompanied by neuritis or systemic symptoms such as fever, malaise, arthralgia, or edema.  
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Since HAART for AIDS treatment has become available in countries where leprosy is 
endemic, around 41 cases of leprosy reaction associated to IRIS have been described in the 
literature (Tables 1 and 2) (Pavie et al., 2009). It is worth to notice that the majority of the 
patients were paucibacillary (65,8%) and most of them (90,2%) developed reversal reaction 
with only 4 cases of Erythema nodosum leprosum published (Tables 1 and 2). The mean 
time that patients developed reaction after initiation of HAART was 18.95 (4-172) weeks 
(median:8, Mode:8, standard deviation:31,1)(Tables 1 and 2). Twenty three (56.09%) of the 
cases were from Brazil (Pereira et al., 2004; Visco-Comandini et al., 2004; Trindade et al., 
2005; Talhari et al., 2007; Caruso et al., 2007; Batista et al., 2008; Deps et al., 2008 & Menezes 
et al., 2009), 13 (31.7%)  from India (Narang et al., 2005; Singal et al., 2006; Kharkar et al., 
2007; Kar et al., 2009 &Vinay et al., 2009), 3 (7.31%) from Haiti (Couppié et al., 2004 & Pavie 
et al., 2009), 1 (2.43%) from Uganda(Lawn et al., 2003) and 1(2.43%) from French 
Guiana(Couppié et al., 2004). Thirty one (75.6%) patients were man and 10 (27.3%) women. 
Twelve (27.3%) cases presented neuritis associated to reaction (Tables 1 and 2). 
 
References 
Leprosy/ 
Reaction 
Types 
Weeks on 
HAART 
CD4 Cell/µl 
HIV     IRIS 
Viral load/Ml 
HIV              IRIS 
(Lawn et al., 2003) BT + RR 4 10 70 120,000 1,000 
(Couppie et al., 2004) 
BB + RR 6 87 257 19,000 650 
BT + RR + N 8 130 278 40,701 68 
BT + RR + N 12 31 171 62,700 50 
(Pereira et al., 2004) 
BT +RR 8 73 270 NA NA 
BT +RR 24 35 100 NA NA 
(Visco-Comandini et 
al., 2004) 
BT + RR 8 7 90 NA NA 
(Narang et al., 2005) BT + RR 8 125 280 150,000 1,750 
(Trindade et al., 2005) 
BB+ RR 24 87 NA <80 NA 
BB+ RR+N 4 223 NA NA NA 
BT+ RR 8 430 NA NA NA 
I +RR 8 NA NA <400 NA 
(Singal et al., 2006) BL + RR+N 4 108 224 NA NA 
(Kharkar et al., 2007) 
BT + RR 12 299 504 NA NA 
BT + RR 8 114 184 NA NA 
(Talhari et al., 2007) BT + RR+N 12 92 426 NA 8,300 
(Caruso et al., 2007) BT+ RR 16 NA 57 NA < 80 
(Batista et al., 2008) 
BT + RR+N 8 14 172 21,300 69,000 
BT + RR+N 8 104 235 NA <80 
(Deps et al., 2008) 
BT + RR 10 33  6,310 NA 
BT + RR 4 170  9,230 NA 
Table 1. Characteristics of 21 cases of leprosy reactions associated with immune 
reconstitution inflammatory syndrome published in literature until 2008: 
Abbreviations: BT= Tuberculoid borderline; BB= Borderline borderline; BL= Lepromatous 
borderline; RR= Reversal reaction; N= Neuritis; NA= Not available. 
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References 
Leprosy/ 
Reaction 
Types 
Weeks on 
HAART 
CD4 Cell/µl 
HIV     IRIS 
Viral load/Ml 
HIV             IRIS 
(Menezes et al., 2009) BT+ RR 4 142 499 300 <80 
 BB+ RR 4 37 200 53,000 2,200 
 BT+ RR 8 NA 226 NA <80 
 BT+ RR 10 62 226 NA <80 
 BT+ RR + N 4 85 190 5,700,000 140 
 BB+ RR 8 179 271 39,000 <80 
 BB+ RR 4 160 140 77,204 4,880 
 BT+ RR 16 76 215 180,000 <80 
 BB+ RR 4 NA 408 NA <80 
 BT+ RR 16 NA 171 14,000 <80 
(Kar et al., 2009) BT+RR 7 125 333 NA NA 
(Pavie et al., 2009) MB+RR+N 40 25 110 100,000 <80 
(Vinay et al., 2009) MB+ENL 172 177 892 NA NA 
 MB+RR+N 32 75 170 NA NA 
 PB+RR+N 24 85 251 NA NA 
 MB+ENL 8 99 99 NA NA 
 MB+ENL 112 124 239 NA NA 
 MB+ENL+N 16 31 144 NA NA 
 PB+RR 64 331 374 NA NA 
 PB+RR 20 174 436 NA NA 
Table 2. Characteristics of 20 cases of leprosy reactions associated with immune 
reconstitution inflammatory syndrome published in literature in 2009. Abbreviations: BT= 
Tuberculoid borderline; BB= Borderline borderline; BL= Lepromatous borderline; RR= 
Reversal reaction; N= Neuritis; ENL= Erithema nodosum lepromatosum; NA= Not 
available. 
In the present series, the highest casuistic published so far, 12 cases of leprosy reaction as 
manifestation of IRIS are thoroughly described in order to establish clinical and 
immunological parameters of definition.  
2. Subjects and methods  
2.1 Study design and inclusion criteria  
The Leprosy Laboratory and the Evandro Chagas Clinical Research Institute (IPEC), 
FIOCRUZ, Rio de Janeiro, have been evaluating coinfected HIV/M. leprae patients since 
1989. Both institutions are reference centers in Rio de Janeiro for these diseases and so far, a 
total of 100 patients have been followed.  
For the purpose of this study, we have reviewed the charts of all patients coinfected with 
M. leprae and HIV who were referred to the Leprosy laboratory/Fiocruz and the IPEC 
between 1997 and 2010. Inclusion criteria were based on the definition criteria proposed 
by French et al (French et al., 2004). Thus, reversal reaction as a manifestation of IRIS was 
defined as the presence of reaction any time during the first 6 months of HAART 
associated to decrease >1 log in HIV-1 viral load. In addition, it was defined in HAART 
naïve patients with no previous laboratory tests data (Viral load or CD4 lymphocytes 
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count), if reaction was present during the first 6 months after initiation of HAART 
associated to undetectable HIV-1 viral load.  
Since the introduction of HAART for AIDS treatment by the Brazilian government in 1997 
until the year of 2010, 33 patients had leprosy reaction under HAART, 12 of which were 
diagnosed with IRIS and were grouped into the case series presented in the present study.  
Case reports of 10 of these patients have been published (Menezes et al., 2009) but additional 
data was obtained and as they are part of the cohort studied they were maintained to 
compose the present case series.  
2.2 Definitions and clinical routine  
All patients followed the clinic routine dermatological and neurological evaluation. For 
diagnostic purposes, skin biopsies were obtained by punch. Samples were routinely 
processed, paraffin embedded, and stained with hematoxylin and eosin (H&E) and Wade’s 
modification of the Ziehl-Nielsen method for detection of acid-fast bacilli (2 sections of each 
staining). Slit skin smears were obtained from six body sites (one from each earlobe, one 
from each elbow, one from a lesion and one from the contra-lateral knee). The smears were 
stained for acid-fast bacilli (AFB) by Ziehl-Neelsen techniques. The bacilloscopic index (BI) 
was calculated using the Ridley & Jopling logarithmic scale (Ridley & Jopling, 1966), based 
on analysis of 100 fields. The lepromin test was measured 30 days after the intradermal 
injection of 0.1 mL of heat-killed M. leprae in the anterior forearm. The result was either 
scored as negative if <5 mm, or positive if ≥5 mm. Leprosy was then diagnosed and 
classified according to Ridley-Jopling criteria(Ridley & Jopling, 1966). The diagnosis of 
reversal reaction was histophatologically defined on the presence of epithelioid cells 
granuloma. In this study we identified two main patterns of reversal reaction depending on 
the severity of the tissue inflammatory changes (Ridley 1969): 
 mild acanthosis and exocytosis; well developed cohesive epithelioid granulomas 
intermingled with few lymphocytes; blood vessels, arrector pili muscles, adnexa and 
nerve bundles; sparse multinucleated cells and small foci of red blood cell 
extravasation. 
 Exuberant changes as moderate to severe acanthosis, spongiosis and exocytosis; 
epithelial apoptosis and basal epidermal erosion; severe dermal inflammatory 
infiltration, including granulomas dissociated by marked edema or centered by 
necrosis, as well as numerous giant cells and red blood cell extravasation. 
All the patients were treated for leprosy with multidrug therapy. Reversal reaction was 
treated following recommendations of the Brazilian Ministry of Health, with a daily 
morning dose of prednisone, starting with 1mg/kg for 1 month, followed by a 10mg/month 
progressive reduction. 
Diagnosis of HIV infection followed the Brazilian Ministry of Health regulations, which 
include the performance of two tests; the immune-enzymatic method (ELISA) plus immune-
fluorescence or Western Blot (National STD/AIDS program of Brazil, 2008). The CD4 cell 
count and viral load were determined around the time of HIV diagnosis and again around 
the time of leprosy diagnosis (defined as the first time the patient visited a health center 
with signs of leprosy). HAART was started at CD4 cell count of less than or equal to 200 
cells/L or if an opportunistic infection was diagnosed (National STD/AIDS program of 
Brazil, 2008). To control the HIV infection, the patients were submitted to periodical clinical 
evaluation and routine laboratory tests. The exchange of information related to the 
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evolution of both infections is a routine at the Units, and remained under the responsibility 
of the professionals involved in the study.  
2.3 Data collection and statistical analysis 
Pertinent data were collected from the patient charts at both institutions. All analysis were 
performed using SPSS 16.0. The difference of the CD4 lymphocytes count and HIV viral 
load before and at the onset of reversal reaction associated with IRIS was analysed by the 
Wilcoxon test. 
2.4 Ethical concerns  
The study was approved by the ethics committee of the Oswaldo Cruz Institute and the 
IPEC. 
3. Results 
Among the total 33 patients experiencing leprosy reversal reaction under HAART, 12 
(36.3%) met the predetermined IRIS criteria. Demographic, clinical and laboratory data of 
these 12 patients are presented in Table 3 (Figure 1). Ten patients were initially diagnosed 
with HIV infection. Significantly, HAART induced reaction in nine patients who had not 
been diagnosed with leprosy. All but one patient received standard treatment for reaction 
with a daily oral dose of prednisone. Five patients needed prolonged use of prednisone for 
up to 12 months (Table 3).  
 
Case Age/Sex 
Leprosy/ 
reaction 
types 
Lesion 
number/ 
complication 
Lepromin 
test (mm) 
 
BI 
Time in 
prednisone 
(months) 
1 48/M BT/RR 2/ none 12 0 0 
2 33/F BB/RR >20/ ulcer 10 0.5 9 
3 39/M BT/RR >10/ulcer 6 0 12 
4 34/M BT/RR >20/none 0 0 8 
5 28/M BT/RR + N >20/none 0 0 10 
6 46/M BB/RR 1/none 12 0.57 11 
7 22/M BB/RR >20/none 0 2.25  
8 28/M BT/RR 1/ulcer 9 0 6 
9 22/F BB/RR 2/none 0 0.5 2 
10 54/M BT/RR >20/none 0 0 0 
11 27/M BT/RR >20/ulcer NA 0 6 
12 M BB/RR >10/none 10 0.57 9 
Table 3. Clinical and epidemiological data of 12 patients with defined IRIS.BT= Borderline 
Tuberculoid, BB= Borderline Borderline, RR= reversal reaction; N=Neuritis 
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Fig. 1. Clinical pattern of reversal reaction skin lesions. 
1A - Clean, ulcerated plaque with well-defined borders. 1B - Infiltrated and erythematous 
plaques with a scaly surface and irregular borders. 1C – Erythematous, queloid-like plaque 
with small central ulcerations. 1D - Disseminated urticariform lesions of various sizes. 
The clinical or laboratory findings of all patients showed immune suppression prior to 
reversal reaction diagnosis. However, only 5 patients had opportunistic infection, namely 
pneumocistosis, esophageal candidiasis, neurotoxoplasmosis and disseminated tuberculosis. 
Moreover, by the time reaction occurred during HAART treatment, most of the patients had 
an increase of the CD4/CD8 T lymphocyte rate, mainly due to increase of CD4 cell count 
mean of 204.5 cells/L (92-446cells/L) (Table 4) (Figure 2). Nine patients had an 
undetectable viral load when reaction developed and three had a mean viral load reduction 
of 2.4 log (1.4 - 4.6 log) (Table 4) (Figure 2). All patients were treated for HIV with regimens 
containing two nucleoside reverse transcriptase inhibitors in combination with a protease 
inhibitor (8.33%), a boosted protease inhibitor (33.33%), or a nonnucleoside reverse 
transcriptase inhibitor (58.33%) (Table 4). The mean time the patients presented reversal 
reaction after starting HAART was 7.8 weeks (Table 4). 
All patients presented erythematous infiltrated plaques and were in the borderline spectrum 
of leprosy. Four patients had complicated ulcerated lesions (figure 1A & 1C) (Table 3). The 
histopathological features observed in all the skin biopsies were fulfilled the patterns 
described for the diagnosis of reversal reaction with tissue severity (figure 3), ranging from 
heavy infiltration, foci of necrosis and extensive involvement of the epidermis (figure 3C & 
3D), to moderate cellular infiltration with well-formed granulomas (figure 3A & 3B) (Table 
5). There was evidence of fragmented acid-fast bacilli in 6 skin biopsies (Table 5). Two 
samples (cases 1 and 11) showed unusually extensive multinucleated cells permeating the 
granulomas (Table 5). The biopsy of patient 2 had heavy dermal edema and marked 
inflammatory infiltration, including some polymorphonuclear leukocytes and many foci of 
necrosis. Initially, these features led to a mistaken diagnosis of erythema nodosum leprosum. 
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After a clinical and histopathological review, reversal reaction superimposed to a 
multibacillary background was established.  
 
Case HAART regimen 
Weeks on 
HAART 
CD4 Cell/µl
HIV     IRIS 
Viral load/Ml 
HIV                IRIS 
1 AZT+3TC+NFV 4 142 499 300 <80 
2 AZT+ DDI+EFVZ 4 37 200 53,000 2,200 
3 AZT+ DDI+EFVZ 8 NA 226 NA <80 
4 D4T+ 3TC+ NVP 10 62 226 NA <80 
5 D4T+3TC+LPV/ RTV 4 85 190 5,700,000 140 
6 AZT+3TC+LPV/ RTV 8 179 271 39000 <80 
7 TDF+ 3TC+ATV/ RTV 4 160 140 77,204 4880 
8 AZT+ 3TC+EFVZ 16 76 215 180,000 <80 
9 AZT+3TC+LPV/ RTV 4 NA 408 NA <80 
10 D4T+ 3TC + EFVZ 16 NA 171 14000 <80 
11 AZT+3TC+EFVZ 12 03 173 407,800 <80 
12 AZT+3TC+EFVZ 4 125 571 321,560 <80 
Table 4. Laboratory data of the 12 patients with reversal reaction and defined IRIS 
Abreviations: NA= not available. AZT= Zidovudine; 3TC= Lamivudine; D4T= Stavudine; 
DDI= Didanosine; TDF: Tenofovir, NVP= Nevirapina; EFVZ= Efavirenz, NFV= Nelfinavir; 
ATV/RTV= Atazanavir/ Ritonavir; LPV/RTV= Lopinavir/Ritonavir. 
 
 
 
Fig. 2. Longitudinal analysis of CD4 lymphocytes count and HIV viral load before and at the 
onset of reversal reaction/IRIS. The mean increase of the CD4 cells count and the mean 
decrease of the HIV viral load were significant (p=0,007 and p=0,003, respectively). 
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Case 
AFB 
(ILB) 
Granuloma  
Giant 
cells a 
lymphocyte
necrosis 
b 
Severeness 
1 0 +++ 20% + Severe 
2 2.6 ++ 20% ++ Severe 
3 0 + 15% + Severe 
4 1 - 30% + Severe 
5 3 - 20% - Mild 
6 0 + 30% - Mild 
7 2.8 + 20% - Mild 
8 0 + 20% - Mild 
9 0 + 20% ++ Severe 
10 1.9 ++ 19% + Severe 
11 0 +++ 25% ++ Severe 
12 1 ++ 20% - Severe 
Table 5. Histopathological data of the 12 patients with reversal reaction and defined 
IRISpatients. In relation to control. Symbols: a) + = few, ++ = several, +++ = many, -=not 
observed;  b) + = little, ++ = moderate, -=not observed. 
 
 
Fig. 3. Histopathological patterns of skin lesions in IRIS patients 
A. Epidermis with intraepithelial lymphocytes and apoptosis; dermis showing cohesive 
tuberculoid granulomas with multinucleated giant cells in RR (pat. 6); B. Angled epithelioid 
granuloma dissociating adnexa in RR(pat. 5); C, D. Severe epidermal changes, dermal 
edema, and epithelioid granulomas with foci of necrosis (inset) in RR type D (pat. 9 and 2, 
respectively; H&E, original magnification, X200). 
4. Discussion  
As observed in the present case series, in the HAART era, leprosy reaction associated with 
IRIS appears to be a frequent event in coinfected patients. The 36% reversal reaction rate in 
coinfected patients undergoing HAART is similar to that estimated for tuberculosis as a 
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manifestation of IRIS (French., 2009). Interestingly, HAART triggered reversal reaction in 
88% of the patients not previously known to have leprosy. As likewise seen in the literature 
(Table 1 and 2), most of the present IRIS cases associated to leprosy had the predominantly 
borderline-tuberculoid form. The borderline forms are considered the most unstable in that 
the immunological capability of the patient to restrain the infection is only partial. During 
reversal reaction, high amounts of inflammatory cytokines such as interferon gamma and 
tumor necrosis factor are produced, reflecting the immune activation characteristics of skin 
lesions with a tuberculoid pattern (Nery et al., 2000). 
Although the moment of infection for either HIV or leprosy is difficult to establish, most of 
the patients were first diagnosed with HIV. In the present case series the period of time 
elapsed between HAART introduction and leprosy reaction was variable but similar to 
previously described in the literature, which ranges from 4 to 24 weeks (Hirsch et al., 2004). 
In HIV negative individuals, reversal reaction usually occurs during the initial months of 
multidrug therapy. As recently reported, the diagnosis of leprosy is associated with 
improved immune status in HIV infected individuals (Sarno et al., 2008). The appearance of 
clinical signs of M. leprae infection in the form of reversal reaction observed in this series and 
in published case reports is not a manifestation of immune suppression but rather of 
immune reconstitution.  This is further supported by the presence of a positive lepromin test 
in some of the multibacillary patients. 
Among the risks factors associated to the development of IRIS, male gender (Shelburne et 
al., 2005), young age (Ratnam et al., 2006), and immune suppression (Shelburne et al.,  2005; 
Ratnam et al., 2006) were also observed in the present series. Other risk factors, such as short 
interval between initiating treatment for opportunistic infection (OI), a rapid fall in HIV-1 
RNA after HAART, and being ART naïve at the time of OI diagnosis were observed in most 
of the patients(Shelburne et al., 2005). Additional significant predictors include a lower 
baseline CD4 cell percentage, a lower CD4 cell count at ART initiation, and a lower CD4 to 
CD8 cell ratio at baseline were observed in a few cases (Ratnam et al., 2006). In the same 
way, a higher baseline CD8 cell count is associated with IRIS as CD8 cell counts represent 
the presence of immune activation[29, 36, 37] (Ratnam et al., 2006) (Robertson et al., 2006) 
(Cianchetta-Sivori et al., 2007). In a case control study, the nadir CD4 T count of less than 
100 cells was independently predictive of development of IRIS as well as the absolute drop 
in viraemia positively correlated with increasing risk for IRIS (Manabe et al., 2007). In this 
series, 5 cases had less than 100 CD4+ cells/L.   
Absolute CD4 T cell increase was observed in most patients, but in 1 patient a cell count 
decrease was observed. As recently described, absolute CD4 T cell increase is not present in 
all cases of IRIS (French et al., 2004; Shelburne et al., 2006). Approximately 10% of IRIS 
complicated MAC infection occurred in the absence of an increase of CD4 T cells 
count(Manabe et al., 2007). Robertson et al suggested to remove an increase CD4 cell count 
as a sole criterion of IRIS, because CD4 lymphocyte plasma levels do not necessary reflect 
function(Robertson et al., 2006). Immune responses may be restored before a rise in plasma 
CD4 cell count is detected. They proposed that an increase in CD4 T cell count should be 
viewed as supportive of diagnosis rather than required for it.  
Manabe et al suggested that the use of the most potent regimens (boosted protease inhibitors 
[BPIs] and/or non-nucleoside reverse transcriptase inhibitors [NNRTIs]) is an independent 
risk factor for the development of IRIS (Manabe et al., 2007). In particular, the use of BPIs 
was associated with IRIS. All of the patients but one, in the present series, were using either 
one or more of these drugs. In addition, HAART induced reduction of 2.5 logs RNA levels 
has shown the highest risk of IRIS (Manabe et al., 2007). In the present study, a similar log 
reduction was observed in the cases with viral load data. 
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The pathogenesis of IRIS remains speculative. Current theories involve the combination of 
underlying antigen burden, the degree of immune restoration, as well as the host genetic 
susceptibility (Price et al., 2001). According to Murdoch, the antigenic stimulus can be intact, 
“clinically silent” organism or dead or dying organism and their residual antigens 
(Murdoch et al., 2007). A common feature of the cases of IRIS is that clinical presentation of 
the opportunistic infection is often atypical compared with that usually observed in HIV-1 
infected patients (French et al., 2004). On the other hand, the pathogenesis of reversal 
reaction is still not completely understood. Restoration of the M. leprae specific immune 
response has been claimed, but convincing data are lacking. During reversal reaction, high 
amount of inflammatory cytokines are produced reflecting the immune reactivation of the 
skin lesions with tuberculoid pattern (Sampaio et al., 1995; Krutzik et al., 2005).  
Among the various risk factors described for reversal reaction are concomitant infections, 
immunization, and pregnancy (Nery JA et al., 1998). In addition, in the present case series, 
HAART triggered reversal reaction in 88% of the patients not previously known to have 
leprosy. Different from initially expected HIV infection per se did not modify the course of 
the disease, but immune restoration by HAART does appear to worsen reversal reaction. In 
the present series, some patients had numerous lesions and ulcers and needed extended 
corticoid therapy, demonstrating a more intense inflammatory process. Such pattern could 
explain the profound scars left by the reversal reaction lesions that are not observed in non 
HIV patients. This type of presentation with numerous skin lesions and ulcerations is more 
usually seen in type II leprosy reactions which are more frequent in multibacillary patients 
and was never referred in the context of IRIS. On the other hand, patients with tuberculoid 
forms which display strong cellular response to M. leprae, usually have neuritis. 
Surprisingly, only one patient in this series was diagnosed with neuritis. The histological 
findings observed in all patients were typical of reversal reaction (Ridley & Radia,1981) even 
in those presenting AFB+ biopsies. Disorganized and disperse granulomas could be seen in 
some cases, thus rending difficult to classify those patients according to the leprosy 
spectrum (cases 2, 5 and 9). The presence of necrosis only occurred in severe reactions, either 
in small foci or causing liquefaction of the granuloma, followed by fibrosis as in case 3, 
leaving profound scars. In some other cases, however, the granulomas take typical 
tuberculoid characteristics, with cohesive epithelioid cells surrounded by a lymphocytic 
halo. The presence of low number of AFB has already been described in borderline 
tuberculoid lesions (Ridley & Jopling, 1966).  
Treatment of complications due to IRIS in other coinfections is frequently necessary to 
minimize short-term morbidity but in the long-term follow-up, outcome appears to be good 
(Murdoch et al., 2007; Riddell et al., 2007). In the present series the patients were treated 
with prednisone as standard for reversal reaction, and had a favorable evolution in spite of 
the severity of disease or the need of a short extension of the use of corticoids. Prednisone is 
the drug of choice for treating reversal reaction because it reduces nerve edema, exerts an 
immunosuppressive effect, and decreases post-inflammatory scar formation (Naafs 1996; 
Andersson et al., 2005). Thus, no modification of the standard therapy for reversal reaction 
is needed in case of IRIS in leprosy patients. 
5. Conclusions 
The present is the largest case series of reversal reaction associated with IRIS in coinfected 
patients described in the literature. In countries like Brazil, where both epidemics overlap 
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and HAART has been broadly administered, leprosy reaction associated to IRIS is prone to 
occur. It might be posited, therefore, that the appearance of clinical signs of M. leprae 
infection in HIV-infected individuals is not a manifestation of immunosuppression but 
rather of immune reconstitution. In the present series, the patients treated with prednisone 
as standard reversal reaction therapy had a favorable evolution despite disease severity. 
Thus, the results of this study clearly indicate that no modification of the standard reversal 
reaction therapy appears necessary in the case of leprosy patients with IRIS. However, there 
is still need of prospective studies to evaluate the association of leprosy reactions and IRIS in 
order to better characterize the pathology and immunology of the coinfection. 
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